

(19) World Intellectual Property
Organization
International Bureau



B3

(43) International Publication Date
16 September 2004 (16.09.2004)

PCT

(10) International Publication Number
WO 2004/079004 A1

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number:

PCT/EP2004/001997

(22) International Filing Date: 27 February 2004 (27.02.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

MI2003A000434

7 March 2003 (07.03.2003) IT

(71) Applicant (for all designated States except US): **ISTITUTO ONCOLOGICO ROMAGNOLO COOPERATIVA SOCIALE A R.L.** [IT/IT]; Corso Mazzini, 65, I-47100 Forlì (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CALISTRI, Daniele** [IT/IT]; Istituto Oncologico Romagnolo Cooperativa Sociale A R.L., Corso Mazzini, 65, I-47100 Forlì (IT). **RENGUCCI, Claudia** [IT/IT]; Istituto Oncologico Romagnolo Cooperativa Sociale A R.L., Corso Mazzini, 65, I-47100 Forlì (IT).

(74) Agents: **BANFI, Paolo** et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/079004 A1

(54) Title: METHOD FOR THE IDENTIFICATION OF COLORECTAL TUMORS

(57) Abstract: Disclosed is a method for the early diagnosis of colorectal carcinoma and determination of pre-cancerous lesions of the colon and rectum based on quantitation of DNA extracted from stool and amplified by PCR techniques.

WU 2004/0/2004

FC 1/21 2004/001571

METHOD FOR THE IDENTIFICATION OF COLORECTAL TUMORS

This invention relates in general to the diagnosis of tumours in human patients and animals. Specifically, it provides a method and kit for the early diagnosis of colorectal carcinoma and determination of pre-cancerous lesions of the colon and rectum. The method of the invention is based on quantitation
5 of DNA extracted from stool and amplified with PCR techniques.

BACKGROUND OF THE INVENTION

In recent years, a great deal of information has been accumulated on the molecular alterations that take place during the development of tumors, such as gene mutations or genomic rearrangements, highlighting the possibility of
10 detecting tumor alterations in biological fluids and consequently indicating the use of these markers as a valid non invasive diagnostic approach.

A tumor that has been widely investigated with this approach is colorectal cancer, which is one of the most common forms of cancer worldwide, with a clinical outcome varying considerably according to the type
15 of lesion and stage of disease at diagnosis (1-3). An early diagnosis is fundamental to reduce morbidity and mortality as a high percentage of patients diagnosed in the early stages of disease are long-term survivors (4). Moreover, the possibility of detecting pre-malignant lesions makes this tumor an ideal target for screening programs. However, although several screening
20 methods are available, a high percentage of individuals do not participate in colorectal cancer screening programs. There are many reasons for this low compliance, such as a lack of knowledge of the benefits of the available screening methods, especially colonoscopy, as well as the unpleasant and troublesome procedures (5).

25 Gene mutations in stool, especially K-ras (6-12) and to a lesser extent p53 (13), APC gene (14,15) and microsatellite instability (16), have been

repeatedly investigated. Results have shown the presence of these molecular alterations in stool in only a fraction of patients, due to the relatively low frequency of single marker alterations in colorectal cancer. Multiple mutations have been analyzed in parallel on the same stool sample and this approach has
5 led to improved test sensitivity, but is expensive, time-consuming and cannot easily be applied to screening programs (17-21).

The diagnostic potential of DNA amplification of exfoliated cells in stool has recently been considered. Preliminary evidence (19-21) has shown that the semi-quantitative evaluation of DNA amplification (L-DNA) of some
10 DNA fragments longer than 200 bp detects more than 50% of colorectal cancers, with a very high specificity.

US application No. 20020004206 discloses a genetic assay for identifying a tumor disease from samples containing exfoliated epithelial cells. The patent application describes an assay comprising a step of PCR
15 amplification of Kras, APC and p53 fragments, followed by semi-quantitative determination of the amplified DNA based on gel-staining.

DESCRIPTION OF THE INVENTION

The present invention is based on a novel, accurate and rapid approach to cancer detection, that allows a better discrimination between affected and
20 non-affected individuals.

Specifically, object of the invention is a method for the quantitation of DNA from stool samples, useful for the early diagnosis of tumours and pre-cancerous lesions of the colon and rectum, which comprises the following steps:

- 25 1) DNA extraction from stool samples;
- 2) PCR amplification of at least three, preferably at least eight different DNA fragments with a length exceeding 100 base pairs, using deoxynucleotide triphosphates or primers labelled with

detectable molecules;

- 3) quantitation of the amplified fragments (amplicons);
- 4) calculation of the total quantity of different amplicons;
- 5) comparison of the values obtained in (4) with a reference value.

5 The DNA extraction can be conducted by conventional techniques using commercially available kits. The DNA fragments amplified in step (2) can span one or more non-overlapping genome regions, including genes and non-coding sequences, provided that the fragment length exceeds 100 bp (base pairs), preferably between 100 and 1000 bp, and more preferably between 100 and 500
10 bp. The fragments can be amplified separately or simultaneously; in the latter case, the amplification products should be distinguished one another by means of appropriate labelling. For example, the primer oligonucleotides or deoxynucleotide triphosphates used in the amplification reaction may carry detectable markers, such as fluorescent molecules (fluorochromes), preferably
15 HEX (Applied Biosystems), 6-FAM (Applied Biosystems) and TAMRA (Applied Biosystems), or other molecules such as biotin, digoxigenin, fluorescein, rhodamine, Cy3, Cy5, 5-FAM Ned, Vic and Pet. The markers are chemically linked to one or more nucleotides within or at the ends of the primer sequences, preferably on the first nucleotide residue, or to the
20 deoxynucleotide triphosphates present in the PCR reaction mixture.

 In a preferred embodiment, the following genome fragments are amplified: exons 5 to 8 of p53 (Gene Bank no. X54156, nt. 13042-13253, 13308-13489, 13986-14124, 14404-14603); genomic regions coding for aminoacids 862-954, 1035-1130, 1288-1402 and 1421-1515 of APC (exon 15
25 - Gene Bank AF127506, M74088).

 In a further preferred embodiment, the amplification products are quantified by automatic DNA sequencers/analysers, preferably using the 3100 Avant Genetic Analyzer® (Applied Biosystems). Other techniques suitable for

fragment amplification according to the invention include immunoenzymatic techniques, real time PCR and chemiluminescence techniques.

The PCR amplification is preferably conducted in the presence of an internal control for the detection of Taq inhibitors. For example, a plasmid
5 containing a sequence, also not human-related, amplifiable with the set of primers used in the amplification of the target DNA, may be added to the PCR reaction mixture. This internal control allows to prevent false negative results due to the presence of Taq inhibitors.

In order to determine the quantity of each amplicon it is necessary to
10 prepare a calibration curve by amplifying known dilutions of genomic DNA or plasmids containing the nucleotide sequences of the target DNA fragments, using the same primers and the same conditions of the test samples. For example, when an automatic fragment sequencer/analyser is used, the AUC (Area Under the Curve) values obtained from the amplification of known
15 quantities of DNA are plotted in a calibration curve; the amounts of DNA in the test samples are then interpolated on the same curve.

The total quantity of the amplification products corresponding to different fragments (i.e. the sum of single amplicon amounts), expressed in weight units, is then compared with a reference or "cut-off" value previously
20 determined on the basis of case series comprising healthy subjects and patients in whom the presence of colorectal tumours or lesions has been established. These cases must include a sufficient number of patients and controls to provide a good confidence interval (CI 95%), preferably at least 50 patients and 50 healthy volunteers.

25 The accuracy, sensitivity and specificity of the method make it particularly useful in the early diagnosis of colorectal tumours, and in the evaluation of the risk or probability of developing such tumours in persons with pre-cancerous colorectal lesions. Further advantages of the method are its

simplicity, speed and low cost.

Another aspect of the invention relates to a kit suitable for carrying out the method described above. The kit may contain labelled oligonucleotides, thermostable DNA polymerase, solutions and reagents for the performance of a PCR reaction and for a quantitation assay (e.g. the immunoenzyme or fluorimetric method). The kit can also contain instructions on the correct operating method.

Figures 1-3: Examples of FL-DNA analysis

Figures 1a and 1b: DNA extracted from stool samples. The levels of amplification of each sample - expressed in weight units (nanograms) - are determined from the corresponding calibration curves (Fig. 2c). The FL-DNA (Fluorescence long DNA) for each sample is given by the sum of the amounts (ng) of three groups of amplicons: p53 - exons 5-8, APC fragments 1-2 and 3-4.

Figures 2a and 2b: electropherograms obtained by amplification of known DNA amounts. The AUC values are normalized (area/100*ng) and plotted against the DNA amount (1, 2, 5, 10 and 20 ng).

Figure 3: ROC curve of FL-DNA analysis of stool samples from patients and healthy donors.

20 Material and Methods

DNA Purification

Approximately 4 g of stool were thawed at room temperature. DNA was extracted after a 15-min homogenization with 16 ml of TE-9 buffer pH 9 (0.5 M Tris-HCl, 20 mM EDTA and 10 mM NaCl) by ULTRA-Turrax T25 (Janke & Kunkel GmbH & Co. KG IKA-Labortechnik, Staufen, Germany). After centrifugation at 5,000 g for 15 min, the supernatant was transferred to a tube containing 5 ml of 7.5 M ammonium acetate (M-Medical, Florence, Italy) and 30 ml of 100% ethanol (Carlo Erba, Milan, Italy). DNA was recovered by

centrifugation at 5,000 g for 15 min at room temperature. Stool samples were suspended in 1.6 ml of ASL buffer and DNA was extracted using the QIAamp DNA Stool Kit (QIAGEN, Hilden, Germany).

FL-DNA Analysis

- 5 Amplifications of exons 5-8 of p53 and fragments 1-4 of APC exon 15 were carried out on 2 μ l of DNA from stool in a total volume of 25 μ l containing 0.4 μ M of each primer, 200 μ M of deoxynucleotide triphosphates, 1 \times reaction buffer with 3.5 mM MgCl₂ and 1 unit of Taq polymerase (QIAGEN). The reaction mixture was subjected to 32 cycles: 60s at 94°C and
10 then 60s at 60 °C for p53 exons, and 58°C for APC fragments, followed by incubation at 72°C for 60s.

- The p53 exons were amplified simultaneously in a single reaction mixture and the 4 APC fragments were amplified in two different mixes (mix 1 - fragments 1 and 2; mix 2 - fragments 3 and 4). For this purpose, primers
15 used for L-DNA analysis were end-labelled with fluorochromes provided by Applied Biosystems (Foster City, CA).

- Amplification 1: exons from 5 to 8 of p53 gene (Gene Bank n. X54156, nt. 13042-13253, 13308-13489, 13986-14124, 14404-14603). Amplification 1 and 2: fragments corresponding to aminoacids 862-954 and 1035-1130 of
20 exon 15 of APC gene (Gene Bank AF127506, M74088). Amplification 3 and 4: fragments corresponding to aminoacids 1288-1402 and 1421-1515 of exon 15 of APC gene (Gene Bank AF127506, M74088).

P53	Exons	Primer name	5'-labelling	Sequence
	5	5-F	6-FAM-	ctcttcctgcagtactcccctgc
		5-R		gccccagctgctcaccatcgcta
	6	6-F		gattgctcttaggtctggcccctc
		6-R	HEX	ggccactgacaaccacccttaacc
	7	7-F	6-FAM	gcgttgctcctaggttggtctg
		7-R		caagtggctcctgacctggagtc
	8	8-F		acctgatttcctactgcctctggc
		8-R	HEX	gtcctgcttgcttacctcgcttagt
APC	Fragment	Primer name	5'-labelling	Sequence
	1	1BF		aactaccatccagcaacaga
		1BR	HEX	taatttggcataaggcatag
	2	2F	6-FAM	cagttgaactctggaaggca
		2R		tgacacaaagactggcttac
	3	3F		gatgtaatcagacgacacag
		3R	HEX	ggcaatcgaacgactctcaa
	4	4F	6-FAM	cagtgatcttcagatagcc
		4R		aaatggctcatcgaggctca

Electrophoresis was carried out using a 3100Avant Genetic Analyzer (Applied Biosystems) equipped with GeneScan Analysis 3.7.

FL-DNA was performed by analyzing the fluorescence intensity of each sample-specific PCR product (Fig. 1ab). The quantification of each sample was calculated by reference to a standard curve (1, 2, 5, 10 and 20 ng) of genomic DNA and expressed as nanograms (Fig. 2abc). To verify the presence or absence of Taq inhibitors, an amplification was performed on all samples with a mix containing 2 μ l of DNA extracted from stool and 25 attograms [ag] of a plasmid with a control sequence. All determinations were performed in

duplicate and repeated in about 20% of samples in which the variation was >20%.

Case Series

Stool samples from 86 patients with primary colorectal cancer were collected in the Gastroenterology Unit and Dept. of Surgery I, Morgagni Hospital, Forlì and in the Depts. of Oncology and General Surgery, Infermi Hospital, Rimini. Stool samples were collected from 62 individuals who proved negative for cancer or benign lesions after colonoscopy, and from laboratory personnel.

Stool samples were obtained at least three days after the administration of laxative treatments in preparation for colonoscopy to allow for the recovery of normal bowel functionality. The fecal specimens were immediately frozen and stored at -70°C for a maximum of two months.

Cancer diagnosis was histologically confirmed and pathological stage was defined according to Dukes' classification: 8 tumors were classified as stage A, 30 as stage B, 37 as stage C and 9 as stage D. Moreover, 19 cancers were located in ascending, 30 in descending, 2 in transverse colon and 35 in the rectal tract. Staging information was not available for only two cases.

Of the 86 patients, 42 were male and 44 were female and median age was 72 years (range 36-90). Of the 62 controls, 29 were male and 33 female and median age was 51 years (range 21-87).

Results

Fluorescence signals ranged from 0 to 283 ng (median 47 ng) in patient stool and from 0 to 87 ng (median 4 ng) in healthy donor stool. No differences in median values were observed with respect to age of patients and size, site and stage of tumor.

When the results from the two approaches were compared, a direct relation was observed, but with a wide variability of FL-DNA levels within

the subgroups defined according to the number of L-DNA high amplifications. Moreover, fluorescence by FL-DNA method was detected in 33 out of the 47 individuals who did not show any high amplification by L-DNA assay. These results are clearly indicative of a higher sensitivity of the fluorescence method
5 than of the conventional approach.

The ROC curve analysis of FL-DNA levels (Fig. 3) shows a good diagnostic accuracy of this approach. In particular, very high specificity ranging from 83% to 95% and high sensitivity ranging from 82% to 72% were observed for the most discriminant cut-offs of 15, 20, 25 and 30 ng of DNA
10 (Table 1). When the cut-off of 25 ng, which provides the best overall accuracy, was analyzed in relation to the different tumor characteristics, sensitivity remained high in patients with small (70%) compared to large tumors (82%) and was similar for the different Dukes' stage tumors (Table 2). More importantly, a similar sensitivity was observed in detecting tumors
15 localized in ascending and descending colon tracts.

Table 1. Sensitivity and specificity of FL-DNA analysis

DNA LEVELS	HEALTHY DONORS		PATIENTS		Sensitivity %	C.I. 95%	Specificity %	C.I. 95%
	Positive	Negative	Positive	Negative				
Cut-off (ng)								
15	10	49	70	15	82	(74-90)	83	(73-93)
20	7	52	70	15	82	(74-90)	88	(80-96)
25	4	55	65	20	76	(67-85)	93	(86-100)
30	3	56	61	24	72	(62-82)	95	(89-100)

Table 2. Sensitivity* as a function of different characteristics in colorectal cancer

Category	No. PATIENTS	POSITIVE	NEGATIVE	SENSITIVITY %
SIZE (cm)				
0.1-4.0	40	28	12	70
≥4.1	38	31	7	82
DUKES' STAGE				
A	8	7	1	88
B	29	25	4	86
C	37	25	12	68
D	9	8	1	89
LOCATION				
Ascending	18	13	5	72
Transverse	2	2	0	100
Descending	30	22	8	73
Rectum	35	28	7	80

* Cut off value 25 ng

REFERENCES

- (1) Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five countries. IARC Scientific Publications No. 143. Lyon: International Agency for Research on Cancer; 1997.
- 5 (2) Boyle P. Faecal occult blood testing (FOBT) as screening for colorectal cancer: the current controversy. *Ann Oncol* 2002;13:16-8.
- (3) Strul H, Arber N. Fecal occult blood test for colorectal cancer screening. *Ann Oncol* 2002;13:51-6.
- (4) Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et
10 al., editors. SEER Cancer Statistics Review, 1975-2000. Bethesda (MD): National Cancer Institute; 2003. Available from: URL: http://seer.cancer.gov/csr/1975_2000, 2003.
- (5) Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in
15 screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests and stool screening using molecular markers. *CA Cancer J Clin* 2003;53:44-55.
- (6) Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. *Science* 1992;256:102-5.
- 20 (7) Hasegawa Y, Takeda S, Ichii S, Koizumi K, Maruyama M, Fujii A, et al. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). *Oncogene* 1995;10:1441-5.
- (8) Smith-Ravin J, England J, Talbot C, Bodmer W. Detection of c-Ki-ras
25 mutations in faecal samples from sporadic colorectal cancer patients. *Gut* 1995;36:81-6.
- (9) Villa E, Dugani A, Rebecchi AM, Vignoli A, Grottola A, Buttafoco P, et al. Identification of subjects at risk for colorectal carcinoma through

a test based on K-ras determination in the stool. Gastroenterology 1996;110:1346-53.

- 5 (10) Nollau P, Moser C, Weinland G, Wagener C. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int J Cancer 1996;66:332-6
- (11) Puig P, Urgell E, Capella G, Sancho FJ, Pujol J, Boadas J, et al. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. Int J Cancer 2000;85:73-7.
- 10 (12) Prix L, Uciechowski P, Bockmann B, Giesing M, Schuetz AJ. Diagnostic biochip array for fast and sensitive detection of K-ras mutation in stool. Clin Chem 2002;48:428-35.
- (13) Eguchi S, Kohara N, Komuta K, Kanematsu T. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996;77:1707-10.
- 15 (14) Deuter R, Muller O. Detection of APC mutation in stool DNA of patients with colorectal cancer by HD-PCR. Hum Mutat 1998;11: 84-9.
- (15) Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-20.
- 20 (16) Traverso G, Shuber A, Olsson L, Levin B, Johnson C, Hamilton SR, et al. Detection of proximal colorectal cancer through analysis of faecal DNA. Lancet 2002;359:403-4.
- (17) Rengucci C, Maiolo P, Saragoni L, Zoli W, Amadori D, Calistri D. Multiple detection of genetic alterations in tumors and stool. Clin Cancer Res 2001;7:590-3.
- 25 (18) Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-65.

- (19) Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. *Gastroenterology* 2000;119:1219-27.
- 5 (20) Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. *Clin Colorectal Cancer* 2003;3:47-53.
- 10 (21) Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool. *Clin Gastr Hep* 2003;1:377-83.

CLAIMS

1. A method for determining the presence of colorectal tumors or pre-cancerous lesions in a human subject, which comprises:
 - 5 a) DNA extraction from stool samples;
 - b) PCR amplification of at least three different DNA fragments with a length of 100 base pairs or more, using deoxynucleotide triphosphates or primers labelled with detectable markers;
 - c) quantitation of the amplified fragments (amplicons);
 - 10 d) calculation of the total amount of different amplicons;
 - e) comparison of the values obtained in (d) with a reference value.
2. A method according to claim 1, wherein the detectable markers used in step (b) are fluorescent molecules.
3. A method according to claim 2, wherein said fluorescent molecules are
 - 15 selected from HEX, 6-FAM and TAMRA.
4. A method according to claims 1-3, wherein at least 8 different DNA fragments are amplified in step (b).
5. A method according to claim 1, wherein the DNA fragments are from 100 to 500bp.
- 20 6. A method according to claim 1, wherein the DNA fragments span different regions of p53 or APC genes.
7. A method according to claim 6, wherein p53 fragments corresponding to exons 5-8 are amplified using the following pairs of primers:
 - a) ctcttctgcagtactcccctgc; gcccagctgtcaccatcgcta;
 - 25 b) gattgctcttaggtctggccctc; ggccactgacaaccacccttaacc;
 - c) gcgttgctcctaggttggtctg; caagtggctcctgacctggagtc;
 - d) acctgattccttactgcctctggc; gtctgcttgcttacctcgcttagt;
8. A method according to claim 6, wherein APC fragments are amplified

using the following pairs of primers:

- a) aactaccatccagcaacaga; taattggcataaggcatag;
 - b) cagttgaactctggaaggca; tgacacaaagactggcttac;
 - c) gatgtaatcagacgacacag; ggcaatcgaacgactctcaa;
 - 5 d) cagtgatcttcagatagcc; aaatggctcatcgaggctca
9. A method according to claims 1-8, wherein the amplicon quantities are interpolated on a calibration curve obtained from known DNA amounts.
10. A method according to claim 1, wherein the amplicons are quantified with an automatic sequencer/analyser or using fluorimetric, colorimetric,
- 10 radioactive or spectrophotometric detection systems.
11. A method according to claim 1, wherein the reference value is determined on the basis of case series comprising healthy subjects and patients affected by colorectal tumor or lesions.
12. A kit containing oligonucleotides, labelling agents, a thermostable DNA
- 15 polymerase and user instructions to carry out the method of claims 1-11.

Fig.1a

p53





Fig. 1b

APC

APC



2/4

Fig. 2a




Fig. 2b








Fig. 2c



4/4

Fig. 3



SEQUENCE LISTING

<110> ISTITUTO ONCOLOGICO ROMAGNOLO COOPERATIVA SOCIALE A R.L.

<120> METHOD FOR THE IDENTIFICATION OF COLORECTAL TUMORS

<130> 6988MEUR

<160> 16

<170> PatentIn version 3.1

<210> 1

<211> 23

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 1
ctcttcctgc agtactcccc tgc 23

<210> 2

<211> 23

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 2
gccccagctg ctcaccatcg cta 23

<210> 3

<211> 24

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 3
gattgctctt aggtctggcc cctc 24

<210> 4

<211> 24

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 4
ggccactgac aaccaccctt aacc 24

<210> 5

<211> 24

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 5

gcgttgctc ctaggttggc tctg

24

<210> 6

<211> 23

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 6

caagtggctc ctgacctgga gtc

23

<210> 7

<211> 25

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 7

acctgatttc cttactgcct ctggc

25

<210> 8

<211> 25

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 8

gtcctgcttg cttacctcgc ttagt

25

<210> 9

<211> 20

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 9

aactaccatc cagcaacaga

20

<210> 10

<211> 20

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 10
taatttggca taaggcatag 20

<210> 11
<211> 20
<212> DNA
<213> Unknown

<220>
<223> synthetic oligonucleotide

<400> 11
cagttgaact ctggaaggca 20

<210> 12
<211> 20
<212> DNA
<213> Unknown

<220>
<223> synthetic oligonucleotide

<400> 12
tgacacaaag actggcttac 20

<210> 13
<211> 20
<212> DNA
<213> Unknown

<220>
<223> synthetic oligonucleotide

<400> 13
gatgtaatca gacgacacag 20

<210> 14
<211> 20
<212> DNA
<213> Unknown

<220>
<223> synthetic oligonucleotide

<400> 14
ggcaatcgaa cgactctcaa 20

<210> 15
<211> 20
<212> DNA
<213> Unknown

<220>
<223> synthetic oligonucleotide

<400> 15

cagtgatctt ccagatagcc

20

<210> 16

<211> 20

<212> DNA

<213> Unknown

<220>

<223> synthetic oligonucleotide

<400> 16

aaatggctca tcgaggctca

20

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data, PAJ, Sequence Search		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/42502 A (EXACT LAB INC) 14 June 2001 (2001-06-14) the whole document	1-12
X	WO 02/092858 A (EXACT SCIENCES CORP) 21 November 2002 (2002-11-21) the whole document	1-12
X	AHLQUIST D A ET AL: "COLORECTAL CANCER SCREENING BY DETECTION OF ALTERED HUMAN DNA IN STOOL: FEASIBILITY OF A MULTITARGET ASSAY PANEL" GASTROENTEROLOGY, W.B.SAUNDERS COMPANY, PHILADELPHIA, US, vol. 119, no. 5, November 2000 (2000-11), pages 1219-1227, XP001118414 ISSN: 0016-5085 the whole document	1-12
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*Z* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">28 June 2004</div>	Date of mailing of the international search report <div style="text-align: center;">08/07/2004</div>	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <div style="text-align: center;">Hermann, P</div>	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 723 298 A (OOMMEN ABRAHAM ET AL) 3 March 1998 (1998-03-03) claim 15	12
A	RENGUCCI C ET AL: "Multiple detection of genetic alterations in tumors and stool." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. MAR 2001, vol. 7, no. 3, March 2001 (2001-03), pages 590-593, XP002286121 ISSN: 1078-0432 the whole document	1-12
A	WO 00/58514 A (EXACT LAB INC) 5 October 2000 (2000-10-05) the whole document	1-12
A	US 5 811 239 A (FRAYNE ELIZABETH GAY) 22 September 1998 (1998-09-22) example 1: nucelotide sequence of p53. primer 1 (for SEQ. ID. 2), primer 2 (for SEQ. ID. 4), primer 3 (for SEQ. ID. 5); primer 4, example 1 (for SEQ. ID. 8);	1-12
A	JP 2001 128685 A (IATRON LAB INC) 15 May 2001 (2001-05-15) Human p53 PCR primer 2, claim 2 (for SEQ. ID. 2); primer 6, claim 2 (for SEQ. ID. 6)	1-12
A	US 6 482 803 B1 (ROTH JACK A ET AL) 19 November 2002 (2002-11-19) Human p53 cDNA fragment, example 3; fig.2.	1-12
A	WO 01/73002 A (UNIV DELAWARE ; GAMPER HOWARD B (US); KMIEC ERIC B (US); RICE MICHAEL) 4 October 2001 (2001-10-04) SEQ. ID. 317, claim 7 (for SEQ. ID. 7) SEQ. ID. 1569 (for SEQ. ID. 9) SEQ. ID. 1582 or 1986 (for SEQ. ID. 10) SEQ. ID. 1605 or 1606 (for SEQ. ID. 11) SEQ. ID. 1626 or 1629 or 1630 (for SEQ. ID. 12) SEQ. ID. 1674 (for SEQ. ID. 13) SEQ. ID. 1749 (for SEQ. ID. 16)	1-12
A	WO 99/06598 A (ONCORMED INC) 11 February 1999 (1999-02-11) Example 6 page 46 (for SEQ. ID. 7)	1-12
A	WO 01/18252 A (EXACT LAB INC) 15 March 2001 (2001-03-15) Example 3 p. 20 (for SEQ. ID. 9)	1-12
	-/-	

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/42504 A (GOCKE CHRISTOPHER D ; KOPRESKI MICHAEL S (US); PENN STATE RES FOUND (U) 14 June 2001 (2001-06-14) PCR primer APC 6 SEQ. ID. 17 (for SEQ. ID. 14) -----	1-12
A	WO 95/32731 A (MEDICAL RES COUNCIL ; TOWNSEND ALAIN ROBERT MICHAEL (GB); UNIV OXFORD) 7 December 1995 (1995-12-07) SEQ. ID. 16 (for SEQ. ID. 15) -----	1-12

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0142502	A	14-06-2001	AU 1804401 A AU 4714201 A AU 7130100 A CA 2393709 A1 CA 2393864 A1 CA 2394921 A1 EP 1238103 A2 EP 1238106 A2 EP 1238113 A2 JP 2003516138 T JP 2003516161 T JP 2003516162 T WO 0142502 A2 WO 0142503 A2 WO 0142781 A2	18-06-2001 18-06-2001 18-06-2001 14-06-2001 14-06-2001 14-06-2001 11-09-2002 11-09-2002 11-09-2002 13-05-2003 13-05-2003 13-05-2003 14-06-2001 14-06-2001 14-06-2001
WO 02092858	A	21-11-2002	US 2002004206 A1 WO 02092858 A2	10-01-2002 21-11-2002
US 5723298	A	03-03-1998	AU 4346597 A WO 9811255 A1	02-04-1998 19-03-1998
WO 0058514	A	05-10-2000	US 6143529 A AU 761722 B2 AU 3918900 A CA 2369045 A1 EP 1185693 A2 JP 2002539848 T WO 0058514 A2	07-11-2000 05-06-2003 16-10-2000 05-10-2000 13-03-2002 26-11-2002 05-10-2000
US 5811239	A	22-09-1998	NONE	
JP 2001128685	A	15-05-2001	NONE	
US 6482803	B1	19-11-2002	NONE	
WO 0173002	A	04-10-2001	AU 4948801 A CA 2404780 A1 EP 1268768 A2 JP 2003528607 T WO 0173002 A2 US 2003217377 A1 US 2004014057 A1 US 2003051270 A1 AU 6527701 A CA 2410523 A1 EP 1297122 A2 WO 0192512 A2 US 2003236208 A1 AU 7906901 A CA 2417344 A1 EP 1364008 A2 WO 0210364 A2 US 2003215947 A1	08-10-2001 04-10-2001 02-01-2003 30-09-2003 04-10-2001 20-11-2003 22-01-2004 13-03-2003 11-12-2001 06-12-2001 02-04-2003 06-12-2001 25-12-2003 13-02-2002 07-02-2002 26-11-2003 07-02-2002 20-11-2003
WO 9906598	A	11-02-1999	AU 8776898 A WO 9906598 A2 US 2003096236 A1	22-02-1999 11-02-1999 22-05-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9906598	A		AU 9292898 A	08-03-1999
			EP 0994946 A1	26-04-2000
			JP 2001514887 T	18-09-2001
			WO 9909164 A1	25-02-1999
WO 0118252	A	15-03-2001	US 6586177 B1	01-07-2003
			AU 7827600 A	10-04-2001
			CA 2384368 A1	15-03-2001
			EP 1212468 A2	12-06-2002
			JP 2003508083 T	04-03-2003
			WO 0118252 A2	15-03-2001
			US 2004014104 A1	22-01-2004
WO 0142504	A	14-06-2001	US 6630301 B1	07-10-2003
			AU 1935701 A	18-06-2001
			CA 2393669 A1	14-06-2001
			WO 0142504 A2	14-06-2001
			US 2003175770 A1	18-09-2003
			US 6511805 B1	28-01-2003
WO 9532731	A	07-12-1995	AU 2623795 A	21-12-1995
			EP 0762891 A1	19-03-1997
			WO 9532731 A2	07-12-1995
			JP 10504702 T	12-05-1998

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)